194 related articles for article (PubMed ID: 26381553)
1. The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma.
Mabray MC; Barajas RF; Villanueva-Meyer JE; Zhang CA; Valles FE; Rubenstein JL; Cha S
AJNR Am J Neuroradiol; 2016 Jan; 37(1):74-9. PubMed ID: 26381553
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma.
Rubenstein JL; Wong VS; Kadoch C; Gao HX; Barajas R; Chen L; Josephson SA; Scott B; Douglas V; Maiti M; Kaplan LD; Treseler PA; Cha S; Hwang JH; Cinque P; Cyster JG; Lowell C
Blood; 2013 Jun; 121(23):4740-8. PubMed ID: 23570798
[TBL] [Abstract][Full Text] [Related]
3. Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma.
Maeyama M; Sasayama T; Tanaka K; Nakamizo S; Tanaka H; Nishihara M; Fujita Y; Sekiguchi K; Kohta M; Mizukawa K; Hirose T; Itoh T; Kohmura E
Cancer Med; 2020 Jun; 9(12):4114-4125. PubMed ID: 32314548
[TBL] [Abstract][Full Text] [Related]
4. CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma.
Ikeguchi R; Shimizu Y; Shimizu S; Kitagawa K
Mult Scler; 2018 Aug; 24(9):1212-1223. PubMed ID: 28657431
[TBL] [Abstract][Full Text] [Related]
5. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
[TBL] [Abstract][Full Text] [Related]
6. CXCL13 and CXCL12 in central nervous system lymphoma patients.
Fischer L; Korfel A; Pfeiffer S; Kiewe P; Volk HD; Cakiroglu H; Widmann T; Thiel E
Clin Cancer Res; 2009 Oct; 15(19):5968-73. PubMed ID: 19773382
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
Sasagawa Y; Akai T; Tachibana O; Iizuka H
J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
[TBL] [Abstract][Full Text] [Related]
8. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
9. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma.
Strehlow F; Bauer S; Martus P; Weller M; Roth P; Schlegel U; Seidel S; Scheibenbogen C; Korfel A; Kreher S
J Neurooncol; 2016 Aug; 129(1):165-71. PubMed ID: 27294357
[TBL] [Abstract][Full Text] [Related]
11. Differentiating between Glioblastoma and Primary CNS Lymphoma Using Combined Whole-tumor Histogram Analysis of the Normalized Cerebral Blood Volume and the Apparent Diffusion Coefficient.
Bao S; Watanabe Y; Takahashi H; Tanaka H; Arisawa A; Matsuo C; Wu R; Fujimoto Y; Tomiyama N
Magn Reson Med Sci; 2019 Jan; 18(1):53-61. PubMed ID: 29848919
[TBL] [Abstract][Full Text] [Related]
12. Histogram analysis of apparent diffusion coefficient maps for differentiating primary CNS lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim N; Kim HS; Choi CG; Lim YM
AJR Am J Roentgenol; 2015 Apr; 204(4):827-34. PubMed ID: 25794073
[TBL] [Abstract][Full Text] [Related]
13. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.
Geng M; Xiao H; Liu J; Song Y; Fu P; Cheng X; Zhang J; Wang G
Cancer Med; 2018 Aug; 7(8):3889-3898. PubMed ID: 29982995
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
[TBL] [Abstract][Full Text] [Related]
16. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis.
Wang L; Luo L; Gao Z; Liu SF; Liu CJ; Ma DX; Chen JG; Cao WR; Yin AM; Xu JW; Wang SL; Zhuo DJ; Geng B; Zhao SS; Wang FY; Yang N; Guan LX; Gu ZY; Gao CJ
Leuk Lymphoma; 2017 Oct; 58(10):2452-2459. PubMed ID: 28278715
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
[TBL] [Abstract][Full Text] [Related]
19. Higher levels of progranulin in cerebrospinal fluid of patients with lymphoma and carcinoma with CNS metastasis.
Kimura A; Takemura M; Serrero G; Yoshikura N; Hayashi Y; Saito K; Inuzuka T
J Neurooncol; 2018 May; 137(3):455-462. PubMed ID: 29340960
[TBL] [Abstract][Full Text] [Related]
20. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
